Comparison of Choroidal Thickness Change between Ranibizumab and Aflibercept in Age-related Macular Degeneration: Six Month Results.
10.3341/jkos.2017.58.3.296
- Author:
Im Gyu KIM
1
;
Yong Il KIM
;
Jin Seon KIM
;
Jung Ho LEE
;
Kyoo Won LEE
;
Hyun Gu KANG
Author Information
1. Cheil Eye Hospital, Daegu, Korea. flowerchild03@hanmail.net
- Publication Type:Original Article
- Keywords:
Aflibercept;
Polypoidal choroidal vasculopathy;
Ranibizumab;
Subfoveal choroidal thickness;
Wet age-related macular degeneration
- MeSH:
Choroid*;
Humans;
Macular Degeneration*;
Ranibizumab*;
Retrospective Studies;
Tomography, Optical Coherence
- From:Journal of the Korean Ophthalmological Society
2017;58(3):296-304
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To compare the changes in subfoveal choroidal thickness between intravitreal aflibercept and ranibizumab injection in wet age-related macular degeneration (AMD). METHODS: Fifty patients with wet AMD patients who were treated with aflibercpet or ranibizumab were evaluated retrospectively. All patients were treated with pro re nata after 3 consecutive monthly injections and were followed up for at least 6 months. We measured subfoveal choroidal thickness (SFCT) using enhanced depth imaging spectral-domain optical coherence tomography before the first injection and 1, 2, 3, and 6 months after initial injection. RESULTS: The SFCT measures before initial injection and 1, 2, 3, and 6 months after initial injection were 244.94 ± 103.77 µm, 219.04 ± 95.89 µm, 208.74 ± 91.03 µm, 203.64 ± 91.35 µm, and 226.98 ± 96.79 µm in the aflibercept group (25 eyes) and 222.68 ± 102.04 µm, 210.23 ± 95.91 µm, 203.66 ± 99.39 µm, 197.27 ± 100.25 µm, and 210.32 ± 111.86 µm in the ranibizumab group (28 eyes). Mean change in SFCT was greater in the aflibercept group at 1 month, 2 months, and 3 months after initial injection (p < 0.05), but there was no significant difference in the mean change in SFCT between the two groups at 6 months after initial injection (p > 0.05). CONCLUSIONS: The decrease in SFCT was greater after aflibercept injection than ranibizumab injection in 3 consecutive months. However, at 6 months after initial injection, the difference in the change in SFCT was not significant.
